Principal Investigator, A*STAR Singapore Immunology Network (SIgN); Associate Professor, Dept. Pharmacy & Pharmaceutical Sciences, National University of Singapore

Research Area: Cancer antigen discovery; mass spectrometry; immunotherapy; secretion; tumor microenvironment.

Award Citation: The AYSF Committee acknowledges her significant contribution in using affinity mass spectrometry to study human biology, immunology, and diseases and would like to support her efforts in developing neoantigen-based immunotherapy for treating microsatellite stable colorectal cancers.

Bio: Wei Wu received her PhD from the National University of Singapore in 2014 with dual-training in cancer biology and mass spectrometry. In this period, she was supported by the President’s Graduate Fellowship and was the recipient of three international Young Investigator Awards in Berlin, Yokohama and Beijing. During her postdoc in the Netherlands, Wei developed diverse and sensitive affinity tools to measure signaling in the tumor micro-environment (TME), and became interested in paracrine impacts mediated through secretion and cell-cell contact. In 2017, she started her group in Utrecht University with a niche in cancer antigen discovery and TME crosstalk, focusing on the extracellular factors needed for immunosurveillance and T cell function. Since 2021, Wei served as a nominated representative from central Europe in the world Human Proteome Organisation (HUPO) council, and was appointed to the international executive committee of the HUPO Human Immuno-Peptidome Project (HUPO-HIPP). In 2022, she moved back to Singapore to join A*STAR-SIgN, focusing on cancer antigen targeting and understanding tissue microenvironmental crosstalk.

Personal Web: https://www.a-star.edu.sg/sign/people/principal-investigators/wei-wu